21:46 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Cantargia reports Phase I/IIa data for cancer candidate CAN04

In October, Cantargia AB (SSE:CANTA) reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04 led to no serious adverse events. The first part of the open-label, European trial...
08:00 , Nov 19, 2015 |  BC Innovations  |  Product R&D

A solid move

Following its IPO in March, Cantargia AB is shifting the focus of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb affects the tumor microenvironment as well as...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Cantargia preclinical data

Cantargia said its anti-IL-1RAP mAb significantly inhibited tumor growth in an animal model of malignant melanoma. Details were not disclosed. The company said it is evaluating several mAb candidates targeting IL-1 receptor accessory protein (IL-1RAP)...
08:00 , Jan 30, 2012 |  BioCentury  |  Emerging Company Profile

Cantargia: Stemming CML

Tyrosine kinase inhibitors have turned chronic myelogenous leukemia into a chronic disease for many patients, but imposes a financial burden on payers. Cantargia AB thinks that targeting CML stem cells can provide a cost-effective, curative...